Does VALSARTAN Cause Bladder transitional cell carcinoma? 35 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 35 reports of Bladder transitional cell carcinoma have been filed in association with VALSARTAN (valsartan). This represents 0.2% of all adverse event reports for VALSARTAN.
35
Reports of Bladder transitional cell carcinoma with VALSARTAN
0.2%
of all VALSARTAN reports
0
Deaths
27
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From VALSARTAN?
Of the 35 reports, 27 (77.1%) required hospitalization, and 2 (5.7%) were considered life-threatening.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VALSARTAN. However, 35 reports have been filed with the FAERS database.
What Other Side Effects Does VALSARTAN Cause?
Drug ineffective (1,845)
Blood pressure increased (1,682)
Dizziness (1,527)
Headache (1,361)
Hypertension (1,341)
Acute kidney injury (1,301)
Dyspnoea (1,239)
Fatigue (1,156)
Malaise (1,139)
Hypotension (1,032)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which VALSARTAN Alternatives Have Lower Bladder transitional cell carcinoma Risk?
VALSARTAN vs VALTREX
VALSARTAN vs VAMOROLONE
VALSARTAN vs VANCOMYCIN
VALSARTAN vs VANDETANIB
VALSARTAN vs VARDENAFIL